Valuation: Charles River Laboratories International, Inc.

Market Cap 13.91B 11.91B 11.14B 10.2B 19.15B 1,331B 19.41B 132B 51.32B 668B 52.24B 51.1B 2,210B P/E 2026 *
78x
P/E 2027 * 31.2x
Enterprise Value 16.03B 13.72B 12.83B 11.75B 22.06B 1,533B 22.35B 152B 59.11B 770B 60.17B 58.85B 2,546B EV / Sales 2026 *
4.1x
EV / Sales 2027 * 3.89x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -
1 week+5.47%
Current month+26.98%
1 month+34.62%
3 months+85.91%
6 months+74.73%
Current year+47.92%
1 week 279.09
Extreme 279.09
299.22
1 month 216.99
Extreme 216.99
299.22
3 years 91.87
Extreme 91.87
299.22
5 years 91.87
Extreme 91.87
460
10 years 67.23
Extreme 67.23
460
Manager TitleAgeSince
Chief Executive Officer 56 04/05/2026
Director of Finance/CFO 58 05/04/2026
Chief Tech/Sci/R&D Officer 45 11/01/2026
Director TitleAgeSince
Chairman 75 31/12/1999
Director/Board Member 56 04/05/2026
Chairman 69 04/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
+1.32%+3.67%+91.05%+46.88% 13.91B
+1.09%+3.39%+3.50%+25.49% 51.22B
-1.07%+3.69%+479.26%+607.16% 45.38B
+1.44%+5.19%+21.06%+93.98% 41.97B
+1.47%+7.58%+35.29%+21.42% 42.15B
-0.93%-4.80%+17.39%+46.60% 31.95B
-0.60%+2.87% - - 16.73B
+1.32%+6.67%+33.29%+148.62% 17.1B
+0.03%+3.91%+5.84%+35.04% 14.76B
+1.28%+4.95%+84.98%+48.41% 13.91B
Average +0.45%+3.19%+85.74%+119.29% 30.58B
Weighted average by Cap. +0.48%+3.13%+102.66%+145.33%

Financials

2026 *2027 *
Net sales 3.91B 3.35B 3.13B 2.87B 5.38B 374B 5.46B 37.01B 14.42B 188B 14.68B 14.36B 621B 4B 3.43B 3.2B 2.93B 5.51B 383B 5.58B 37.86B 14.76B 192B 15.02B 14.69B 636B
Net income 162M 139M 130M 119M 223M 15.53B 226M 1.54B 599M 7.8B 610M 596M 25.79B 428M 366M 343M 314M 589M 40.92B 597M 4.05B 1.58B 20.54B 1.61B 1.57B 67.94B
Net Debt 2.11B 1.81B 1.69B 1.55B 2.91B 202B 2.95B 19.99B 7.79B 101B 7.93B 7.76B 336B 1.63B 1.4B 1.31B 1.2B 2.24B 156B 2.27B 15.43B 6.01B 78.33B 6.12B 5.99B 259B
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
-
Date Price Change
21/08/26 US$295.33 +1.32%
20/08/26 US$291.48 +0.58%
19/08/26 US$289.80 +3.84%
18/08/26 US$279.09 -2.63%
17/08/26 US$286.63 +2.36%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
291.45USD
Average target price
281.00USD
Spread / Average Target
-3.59%

Quarterly revenue - Rate of surprise